Company news
Travere Therapeutics, Inc. (NASDAQ:TVTX) news
Travere Therapeutics, Inc. news releases on 6ix. Latest, Sep 16, 2021: Vifor Pharma and Travere Therapeutics announce licensing agreement…
Press releases — page 4
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
September 15, 2021
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
September 14, 2021
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
September 13, 2021
Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
September 6, 2021
Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
August 15, 2021
Travere Therapeutics Reports Second Quarter 2021 Financial Results
July 28, 2021
Travere Therapeutics to Report Second Quarter 2021 Financial Results
July 21, 2021
Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021
June 3, 2021
Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
June 1, 2021
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis
May 24, 2021
Travere Therapeutics Reports First Quarter 2021 Financial Results
May 5, 2021
Travere Therapeutics to Report First Quarter 2021 Financial Results
April 25, 2021
Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
February 28, 2021
Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy
February 17, 2021
Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
February 1, 2021
Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
January 11, 2021
Travere Therapeutics Provides Corporate Update and 2021 Outlook
January 10, 2021
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
November 30, 2020
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
November 15, 2020